FDA says StatStrip Gen 2.0 meters can retain prior patient information, allowing a correct glucose result to enter the wrong patient's record and potentially drive inappropriate treatment.

The U.S. Food and Drug Administration is warning hospitals about a serious recall involving certain Nova Biomedical StatStrip Glucose Hospital Meter Systems Gen 2.0 after reports that previous patient-identification information can remain on the device.

The key problem is not inaccurate glucose measurement.

FDA states that the issue does not affect the analytical performance of the glucose test. Instead, a correctly measured glucose result can be assigned to the wrong patient's medical record if retained patient information is accepted and the mismatch is not recognized. [1]

That creates a medication-safety pathway in which clinicians may act on another patient's glucose result—including potentially administering insulin unnecessarily, delaying needed treatment or failing to treat the patient whose glucose was actually measured.

FDA has identified the recall as its most serious type and says the affected devices should be removed from where they are used or sold until a software update is available.

Which StatStrip Meters Are Affected?

The current FDA removal applies specifically to StatStrip Glucose Hospital Meter System Gen 2.0.

FDA specifically says the removal does not apply to previously released StatStrip models such as Gen 1.86. [1]

The Gen 2.0 problem affects all firmware versions covered by the current action.

The Glucose Value Can Be Correct—and Still Reach the Wrong Patient

This distinction is central to understanding the recall.

Nova Biomedical reported that when a patient-ID or quality-control barcode is scanned, information from a previous patient or QC record may remain on the meter screen.

If that retained information is accepted, the newly generated glucose result may be associated with the wrong patient record. [1]

The analytical measurement itself can therefore be accurate while the clinical information becomes unsafe.

That makes this event different from a glucose meter producing systematically false high or low readings.

The failure occurs in data identity and attribution.

How Could This Lead to a Medication Error?

A glucose value often triggers immediate clinical decisions.

If one patient's result appears in another patient's medical record, clinicians may treat the wrong physiologic problem.

FDA specifically identifies possible consequences including:

• delayed treatment;

• unnecessary treatment, including inappropriate insulin administration; and

• failure to treat the intended patient.

[1]

That does not mean every incorrect patient assignment results in insulin administration or hypoglycemia.

The consequence depends on the actual glucose status and clinical condition of both patients and whether the record mismatch is recognized before treatment.

FDA specifically identifies critically ill patients and infants as being at greater risk of adverse outcomes, including because some patients may be unable to communicate symptoms of hypoglycemia.

One Serious Injury Reported, No Deaths

FDA's October 20 recall page states that, as of October 5, Nova Biomedical had reported one serious injury and no deaths associated with this issue. [1]

The public FDA recall page does not establish that this serious injury was specifically an insulin overdose.

That distinction should be preserved.

FDA identifies inappropriate insulin administration as a plausible consequence of wrong-patient glucose documentation, but the reported serious injury should not be assigned a specific toxicologic mechanism unless FDA provides that connection.

What Hospitals Should Do Now

FDA says Nova Biomedical has recommended removal of affected Gen 2.0 meters from use or sale until the software correction becomes available.

For facilities that cannot immediately substitute another device, FDA lists interim safeguards. These include enabling patient-ID validation when compatible Admission, Discharge and Transfer integration is available, configuring the meter to automatically log operators out after each test, and independently checking patient identity both after barcode scanning and again when the result appears.

If a glucose result is found in the wrong patient's record, facilities should immediately notify the appropriate administrator, flag or remove the erroneous result according to institutional procedures, and alert the treating clinical team so the value is not used for glucose-management decisions.

This is a systems-safety response rather than a new insulin-poisoning treatment protocol.

A Software Fix Is Planned

Nova Biomedical has placed a shipment hold on the affected new-model StatStrip Gen 2.0 systems while corrective actions are developed and validated.

FDA says the company intends to begin a phased software-update rollout in November 2026. [1]

Until the correction is implemented, facilities using affected meters without an alternative device need to maintain the recommended identity-verification safeguards.

Why This Medication-Safety Failure Is Different

MedicalToxic has recently covered several system errors that can create unintended toxic exposure, but the mechanism here is distinct.

In Saline Recall After Potassium Chloride Bag Found Inside Wrong Overwrap, the physical drug inside the package did not match the medication expected from the outer label.

In Iatrogenic Acetylcysteine Overdose: New Review Maps Severe Medication Errors, failures in prescribing, preparation and administration allowed an intended antidote to become an excessive exposure.

The StatStrip recall represents another pathway:

correct sample → correct glucose measurement → wrong patient record → potentially wrong treatment.

The unsafe exposure can therefore arise downstream of diagnostically accurate testing.

What Is Genuinely New?

Nova had already issued earlier customer communications about the patient-ID problem.

The material October 20 development is FDA's public removal communication identifying the action as its most serious recall type, specifying removal of Gen 2.0 systems pending correction and documenting one serious injury and no deaths.

That escalation moves the event beyond a routine device software correction and makes the medication-safety implications directly relevant to MedicalToxic.

Limitations

The FDA communication does not establish that every Gen 2.0 meter has produced a wrong-patient record.

It also does not provide an incidence rate for patient-ID mismatches or clinical harm.

The recall should not be reported as a glucose-accuracy failure, because FDA explicitly states that analytical glucose performance is unaffected.

Likewise, potential downstream outcomes should not be converted into observed cases unless separately documented.

The current evidence supports a narrower conclusion:

a patient-identification software failure can place a valid glucose measurement into the wrong patient's medical record and create a pathway to inappropriate or delayed treatment.

Conclusion

FDA's October 20 StatStrip action highlights an important medication-safety principle: a diagnostic result can be analytically correct and still become dangerous if it is assigned to the wrong patient.

The recall applies to StatStrip Glucose Hospital Meter System Gen 2.0, including models 63685 and 66739, and does not extend to older systems such as Gen 1.86.

FDA reports one serious injury and no deaths associated with the issue.

For hospitals, the immediate priority is patient-identification integrity: remove affected devices when an alternative is available, follow FDA/Nova mitigation instructions where continued use is unavoidable, and promptly correct any glucose result assigned to the wrong record.

References

1. U.S. Food and Drug Administration. (2026, October 20). Hospital Glucose Meter Removal: Nova Biomedical Removes StatStrip Glucose Hospital Meter Systems.